keyword
MENU ▼
Read by QxMD icon Read
search

azathioprine crohn

keyword
https://www.readbyqxmd.com/read/29315147/nonmelanoma-skin-cancer-risk-in-patients-with-inflammatory-bowel-disease-undergoing-thiopurine-therapy-a-systematic-review-of-the-literature
#1
Joshua W Hagen, Melissa A Pugliano-Mauro
BACKGROUND: Azathioprine and 6-mercaptopurine (thiopurines) are common adjunct treatments for inflammatory bowel disease (IBD). Although thiopurine therapy in organ transplant recipients is known to increase nonmelanoma skin cancers (NMSCs), dermatologic literature yields less data regarding NMSC risk of thiopurine use in IBD. OBJECTIVE: The aim of this study was to systematically review current literature on NMSC risk in patients with IBD using thiopurine therapy...
January 8, 2018: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
https://www.readbyqxmd.com/read/29298460/early-infliximab-yields-superior-long-term-effects-on-linear-growth-in-pediatric-crohn-s-disease-patients
#2
Jaeyoung Choi, Ben Kang, Min-Ji Kim, Insuk Sohn, Hae Jeong Lee, Yon Ho Choe
Background/Aims: Information regarding the efficacy of early infliximab treatment in pediatric patients with Crohn's disease (CD) is limited. We aimed to evaluate the impact of early combined immunosuppression on linear growth in pediatric patients with CD by performing step-up comparisons. Methods: This retrospective study included pediatric patients with moderate-to-severe CD, who received a combination therapy with infliximab and azathioprine for at least 3 years and sustained corticosteroid-free remission without loss of response...
January 5, 2018: Gut and Liver
https://www.readbyqxmd.com/read/29212102/-conservative-treatment-of-an-aseptic-abscess-syndrome-with-splenic-abscesses-in-crohn-s-disease
#3
Thomas Göbel, Jutta Rauen-Vossloh, Hubert Georg Hotz, Andree Boldt, Andreas Erhardt
A 24-year old woman with a history of Crohn's disease developed bloody diarrhea and multiple abdominal abscesses, daily fever, leukocytosis, and elevated CRP several months after her immunosuppressive therapy with azathioprine was stopped. Recurrent abscess punctures did not detect any pathogenic germs and neither clinical nor serological response was achieved by administration of different antimicrobial therapies. Additionally, new splenic abscesses arose despite ongoing therapy. Under the suspicion of the rare aseptic abscess syndrome, representing an auto-inflammatory, extra-intestinal manifestation of Crohn's disease, the antimicrobial therapy was stopped and an intravenous therapy with prednisolone was initiated...
December 2017: Zeitschrift Für Gastroenterologie
https://www.readbyqxmd.com/read/29180383/comparative-risk-of-incident-venous-thromboembolism-in-patients-with-inflammatory-bowel-disease-initiating-tumour-necrosis-factor-%C3%AE-inhibitors-or-nonbiologic-agents-a-cohort-study
#4
Rishi J Desai, Joshua J Gagne, Joyce Lii, Jun Liu, Sonia Friedman, Seoyoung C Kim
BACKGROUND: Inflammatory bowel disease (IBD) increases the risk of venous thromboembolism (VTE) by 2 to 3 times. We compared the reduction in risk of incident VTE associated with use of tumour necrosis factor-α (TNF-α) inhibitors versus nonbiologic immunomodulatory agents in patients with IBD. METHODS: This observational cohort study used data from public (Medicaid, 2000-2010; Medicare, 2007-2013) and private (Optum Clinformatics, 2004-2013) health insurance programs in the United States...
November 27, 2017: CMAJ: Canadian Medical Association Journal, Journal de L'Association Medicale Canadienne
https://www.readbyqxmd.com/read/29174208/does-azathioprine-induce-endoscopic-and-histologic-healing-in-pediatric-inflammatory-bowel-disease-a-prospective-observational-study
#5
Francesca Paola Giugliano, Caterina Strisciuglio, Massimo Martinelli, Marialuisa Andreozzi, Sabrina Cenni, Severo Campione, Maria D'Armiento, Annamaria Staiano, Erasmo Miele
BACKGROUND: The new concept of disease remission for pediatric inflammatory bowel diseases (IBD) implies the achievement of mucosal healing. AIMS: We aimed to evaluate endoscopic and histologic healing in children with Ulcerative Colitis (UC) and Crohn's disease (CD) in clinical remission after 52 weeks of Azathioprine. METHODS: From December 2012 to July 2015 we prospectively enrolled IBD children starting Azathioprine. Enrolled patients in clinical remission underwent colonoscopy after 52 weeks...
November 3, 2017: Digestive and Liver Disease
https://www.readbyqxmd.com/read/29150359/azathioprine-induce-acute-submandibular-sialadenitis-in-a-patient-with-crohn-s-disease
#6
Adriana Guerra Romero, José Lázaro Pérez Calle, Pilar López Serrano
No abstract text is available yet for this article.
November 14, 2017: Gastroenterología y Hepatología
https://www.readbyqxmd.com/read/29142522/drug-induced-eosinophilic-pneumonia-in-a-patient-with-crohn-s-disease-diagnosis-and-treatment-using-fraction-of-exhaled-nitric-oxide
#7
Jina Yeo, Hyun Sun Woo, Sang Min Lee, Yoon Jae Kim, Kwang An Kwon, Dong Kyun Park, Jung Ho Kim, Kyoung Oh Kim, Jun-Won Chung
Oral 5-aminosalicylic acid agents (mesalazine and sulfasalazine) and azathioprine are the mainstays of treatment for inflammatory bowel disease. Reports of pulmonary toxicity induced by oral 5-aminosalicylic acid agents or azathioprine in patients with inflammatory bowel disease are very rare; to date, only 38 cases have been reported worldwide. We, herein, report a case involving a 26-year-old man who was diagnosed with eosinophilic pneumonia after using mesalazine and azathioprine for the treatment of Crohn's disease and recovered after treatment...
October 2017: Intestinal Research
https://www.readbyqxmd.com/read/29104132/clinical-and-pharmacokinetic-factors-associated-with-adalimumab-induced-mucosal-healing-in-patients-with-crohn-s-disease
#8
Kenji Watanabe, Takayuki Matsumoto, Tadakazu Hisamatsu, Hiroshi Nakase, Satoshi Motoya, Naoki Yoshimura, Tetsuya Ishida, Shingo Kato, Tomoo Nakagawa, Motohiro Esaki, Masakazu Nagahori, Toshiyuki Matsui, Yuji Naito, Takanori Kanai, Yasuo Suzuki, Masanori Nojima, Mamoru Watanabe, Toshifumi Hibi
BACKGROUND & AIMS: We previously reported results from a prospective randomized controlled trial comparing the efficacy of adalimumab monotherapy vs combination with azathioprine for patients with Crohn's disease (CD) who were naïve to biologics and thiopurines. We performed a sub-analysis of data from this study to evaluate factors associated with endoscopic response and mucosal healing in study participants. METHODS: We compared simple endoscopic scores for CD (SES-CD) in between patients with moderate to severe active CD randomly assigned groups that received adalimumab monotherapy (n=85) or adalimumab in combination with azathioprine (n=91), from June 2011 to June 2014 in Japan...
November 2, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29096949/effect-of-tight-control-management-on-crohn-s-disease-calm-a-multicentre-randomised-controlled-phase-3-trial
#9
Jean-Frederic Colombel, Remo Panaccione, Peter Bossuyt, Milan Lukas, Filip Baert, Tomas Vaňásek, Ahmet Danalioglu, Gottfried Novacek, Alessandro Armuzzi, Xavier Hébuterne, Simon Travis, Silvio Danese, Walter Reinisch, William J Sandborn, Paul Rutgeerts, Daniel Hommes, Stefan Schreiber, Ezequiel Neimark, Bidan Huang, Qian Zhou, Paloma Mendez, Joel Petersson, Kori Wallace, Anne M Robinson, Roopal B Thakkar, Geert D'Haens
BACKGROUND: Biomarkers of intestinal inflammation, such as faecal calprotectin and C-reactive protein, have been recommended for monitoring patients with Crohn's disease, but whether their use in treatment decisions improves outcomes is unknown. We aimed to compare endoscopic and clinical outcomes in patients with moderate to severe Crohn's disease who were managed with a tight control algorithm, using clinical symptoms and biomarkers, versus patients managed with a clinical management algorithm...
October 31, 2017: Lancet
https://www.readbyqxmd.com/read/29069227/bone-mineral-density-and-inflammatory-bowel-disease-severity
#10
C A Lima, A C Lyra, C M C Mendes, M B Lopes, F G Coqueiro, R Rocha, G O Santana
Inflammatory bowel disease (IBD) is associated with low bone mineral density (BMD). In this study, the association between disease severity and BMD in patients with IBD was evaluated. Associations between BMD and the Montreal classification, disease activity and drug therapy were also tested. A cross-sectional prevalence study with a comparison group was conducted. One hundred and twenty-eight patients were evaluated: 68 patients with ulcerative colitis (UC), and 60 with Crohn's disease (CD). The control group consisted of 67 healthy subjects...
October 19, 2017: Brazilian Journal of Medical and Biological Research, Revista Brasileira de Pesquisas Médicas e Biológicas
https://www.readbyqxmd.com/read/29051788/emerging-oral-targeted-therapies-in-inflammatory-bowel-diseases-opportunities-and-challenges
#11
REVIEW
Marcel Vetter, Markus F Neurath
To improve quality of life and prevent long-term risks in patients with inflammatory bowel diseases (IBDs: Crohn's disease, ulcerative colitis), it is essential to suppress inflammatory activity adequately. However, corticosteroids are only suitable for therapy of acute flares and the evidence for positive effects of immunosuppressive substances like azathioprine or 6-mercapropurine is mainly limited to maintenance of remission. In addition, only subgroups of patients benefit from biologicals targeting tumour necrosis factor α or α4β7 integrins...
October 2017: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/28986660/risk-factors-for-rescue-therapy-in-crohn-s-patients-maintained-on-infliximab-after-withdrawal-of-the-immunomodulator-a-long-term-follow-up
#12
Monika Fischer, Sarah C Campbell, Cynthia S J Calley, Debra J Helper, Michael V Chiorean, Hala M Fadda
BACKGROUND: Usefulness of thiopurine and scheduled infliximab combination therapy in non-immunomodulator (IM)-naïve Crohn's disease (CD) patients and the optimal length of dual therapy are still debated. AIMS: To determine proportion of patients developing disease flare requiring rescue therapy and risk factors associated with disease flare after de-escalation of IM from combination therapy. METHODS: Adult CD patients in clinical remission on combination therapy were identified from a large single-center database between 2002 and 2009...
November 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/28967958/visceral-leishmaniasis-infection-in-a-patient-with-crohn-s-disease-treated-with-azathioprine
#13
Teresa Valdés Delgado, Patricia Cordero Ruiz, Francisco Bellido Muñoz
No abstract text is available yet for this article.
October 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28961694/a-severe-neonatal-lymphopenia-associated-with-administration-of-azathioprine-to-the-mother-in-a-context-of-crohn-s-disease
#14
C Thomas, C Monteil-Ganiere, S Mirallié, C Hémont, C Dert, A Léger, C Joyau, D Caldari, M Audrain
Azathioprine is commonly used in Crohn's Diseases. It has been administered to many pregnant women over many years without significant side effects. However, pancytopenia and Severe Combined Immune Deficiency-like disease have been reported in infants whose mothers received azathioprine throughout pregnancy. Moreover, myelotoxicity has been described in patients treated with azathioprine and having a low or absent thiopurine S-methyl transferase (TPMT) activity.Here, we describe the case of a new-born girl found highly lymphopenic (<300 CD3+ T cells) after a positive new-born screening for Severe Combined Immuno Deficiency...
September 2, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28948431/vulvar-involvement-in-pediatric-crohn-s-disease-a-systematic-review
#15
REVIEW
Roberta Granese, Gloria Calagna, Giuliana Morabito, Carmine Carriero, Antonio Perino, Gabriele Tonni, Claudio Romano
PURPOSE: The aim of the study is to report a systematic review (from 2000 to 2017) of all pediatric cases of vulvar Crohn's disease (VCD) and to highlight the key-points for a correct diagnosis and management of this rare condition. METHODS: An electronic search using the Pubmed/Medline, Scopus, EMBASE, Cochrane database and Google Scholar database was performed according to PRISMA guidelines. RESULTS: Twenty pediatric studies and 22 cases of VCD were included for analysis...
September 25, 2017: Archives of Gynecology and Obstetrics
https://www.readbyqxmd.com/read/28940780/prolonged-azathioprine-treatment-reduces-the-need-for-surgery-in-early-crohn-s-disease
#16
Yun Qiu, Bai-Li Chen, Rui Feng, Sheng-Hong Zhang, Yao He, Zhi-Rong Zeng, Shomron Ben-Horin, Laurent Peyrin-Biroulet, Ren Mao, Min-Hu Chen
BACKGROUND AND AIM: Whether an early use of azathioprine (AZA) can alter the natural history of Crohn's disease (CD) remains debated. To evaluate the impact of AZA on disease progression in a cohort of patients with early CD. METHODS: This longitudinal cohort study examined patients with early CD defined as disease duration ≤18 months and no previous use of disease-modifying agents according to Paris definition. The primary outcome was the proportion of CD-related intestinal surgery...
September 22, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28929775/hypersensitivity-to-azathioprine-in-a-patient-with-crohn-s-disease-a-case-report
#17
Mafalda Sousa, Luísa Proença, João Carvalho
Azathioprine (AZA) is commonly used in inflammatory bowel disease and many other medical diseases. The most common adverse events of AZA include gastrointestinal effects, hepatotoxicity, myelotoxicity and pancreatitis.
October 2017: Revista Española de Enfermedades Digestivas
https://www.readbyqxmd.com/read/28922253/long-term-efficacy-safety-and-immunogenicity-of-biosimilar-infliximab-after-one-year-in-a-prospective-nationwide-cohort
#18
Lorant Gonczi, Krisztina B Gecse, Zsuzsanna Vegh, Zsuzsanna Kurti, Mariann Rutka, Klaudia Farkas, Petra A Golovics, Barbara D Lovasz, Janos Banai, Laszlo Bene, Bea Gasztonyi, Tunde Kristof, Laszlo Lakatos, Pal Miheller, Ferenc Nagy, Karoly Palatka, Maria Papp, Arpad Patai, Agnes Salamon, Tamas Szamosi, Zoltan Szepes, Gabor T Toth, Aron Vincze, Balazs Szalay, Tamas Molnar, Peter L Lakatos
BACKGROUND: It has been previously shown that biosimilar infliximab CT-P13 is effective and safe in inducing remission in inflammatory bowel diseases. We report here the 1-year outcomes from a prospective nationwide inflammatory bowel disease cohort. METHODS: A prospective, nationwide, multicenter, observational cohort was designed to examine the efficacy and safety of CT-P13 in the induction and maintenance treatment of Crohn's disease (CD) and ulcerative colitis (UC)...
November 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28917218/erythema-elevatum-diutinum-in-crohn-s-disease-associated-spondyloarthritis-a-rare-vasculitis-an-unusual-association
#19
Maria João Gonçalves, Vasco C Romão, Luís Soares-de-Almeida, Helena Canhão, José Carlos Romeu, Heinz Kutzner, José Alberto Pereira-da-Silva
Erythema elevatum diutinum is a rare neutrophilic dermatoses with vasculitis, which presents as persistent, symmetrical, purple or brownish papules and nodules, mainly in the extensor surface of the limbs. We describe a case of erythema elevatum diutinum and polyarthritis as initial manifestations of Crohn's disease associated spondyloarthritis. A 51-year-old man, from São Tomé e Príncipe, with previous history of treated tuberculosis and chronic hepatitis B infection, was admitted due to 4 months history of polyarthritis, hyperpigmented papules on the extensor surfaces, occasional episodes of bloody mucous diarrhea and significant weight loss...
September 14, 2017: Acta Reumatológica Portuguesa
https://www.readbyqxmd.com/read/28906316/secondary-loss-of-response-to-infliximab-in-pediatric-crohn-s-disease-does-it-matter-how-and-when-we-start
#20
Rishi Bolia, Jeremy Rosenbaum, Vered Schildkraut, Winita Hardikar, Mark Oliver, Donald Cameron, George Alex
OBJECTIVES: A significant proportion of children with Crohn's disease develop a secondary loss of response (LOR) to infliximab. Our aim was to study the impact of initial treatment strategies on secondary LOR. METHODS: We reviewed the medical records of children with Crohn's disease who received scheduled maintenance infliximab therapy for at least 12 months. We compared children who developed LOR with those who did not; with regards to their clinical and laboratory parameters, disease phenotype and treatment strategy before developing LOR...
September 12, 2017: Journal of Pediatric Gastroenterology and Nutrition
keyword
keyword
30477
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"